Overall market sentiment has been high on AcelRx Pharmaceuticals Inc (ACRX) stock lately. ACRX receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ACRX Stock Today?
AcelRx Pharmaceuticals Inc (ACRX) stock is trading at $1.64 as of 11:30 AM on Thursday, Oct 8, a gain of $0.20, or 13.77% from the previous closing price of $1.44. The stock has traded between $1.43 and $1.68 so far today. Volume today is low. So far 1,226,120 shares have traded compared to average volume of 1,735,522 shares.
To see the top 5 stocks in the Drug Manufacturers - Specialty & Generic industry click here.
More About AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system) SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for the reduction of moderate-to-severe acute pain in medically supervised settings.
Click Here to get the full Stock Score Report on AcelRx Pharmaceuticals Inc (ACRX) Stock.
